HHS Bypasses FDA to Allow Sale of Six Unproven Peptides

Key points

• HHS will not take enforcement action against 503A compounding pharmacies for producing BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.
• The policy sidesteps the formal FDA rulemaking process, which requires rigorous safety and efficacy testing, by using a temporary enforcement discretion notice.
• Kennedy Jr. stated he uses some peptides and called himself a 'big fan,' while HHS argued the move shifts consumers away from illicit 'research-use-only' products.
• FDA scientists previously recommended against removing these peptides from the restricted list, citing insufficient evidence of safety or efficacy.
• The policy applies only to small 503A pharmacies, not larger 503B outsourcing facilities, potentially limiting supply to meet high demand.

Background

In July 2026, an FDA advisory panel voted to add these six peptides to the bulk drugs list, though FDA scientists recommended against it. Kennedy Jr. had quietly proposed the enforcement discretion rule earlier in October, following a period of growing gray-market sales of peptides labeled 'for research use only.'

How outlets are covering it

Ars Technica and NBC News highlighted that Kennedy Jr. stacked the July advisory panel with members having ties to the peptide industry, raising conflict-of-interest concerns. Yahoo emphasized that the policy bypasses standard FDA safeguards, such as tests for cancer or birth defects. NPR focused on the practical limitation that small 503A pharmacies may not be able to meet consumer demand. Critics, including the Center for Science in the Public Interest and Public Citizen, argued the move undermines FDA authority and exposes patients to untested risks, while proponents like the Alliance for Pharmacy Compounding called it a 'more accountable alternative' to black-market imports.

Why it matters

The policy sets a precedent for bypassing FDA approval processes for unproven substances, potentially encouraging the sale of other unapproved drugs. It also raises questions about the influence of industry ties on regulatory decisions and the balance between patient access and public safety.

What to watch

HHS is expected to pursue a formal rule change to permanently add the peptides to the bulk drugs list. Compounding pharmacies will need to verify ingredient purity and report side effects, though supply may remain limited due to the 503A restriction.